These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 7049504)

  • 21. Kinetics of the tissue distributions of sulindac and metabolites. Relevance to sites and rates of bioactivation.
    Duggan DE; Hooke KF; Hwang SS
    Drug Metab Dispos; 1980; 8(4):241-6. PubMed ID: 6105058
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction.
    Packer M; Lukas MA; Tenero DM; Baidoo CA; Greenberg BH;
    Am J Cardiol; 2006 Oct; 98(7A):39L-45L. PubMed ID: 17023231
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of once-daily theophylline dose following the morning versus evening administration.
    Trnavská Z; Vondra V; Elis J
    Arzneimittelforschung; 1989 Sep; 39(9):1149-51. PubMed ID: 2590267
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of sulindac metabolism by dimethyl sulfoxide in the rat.
    Swanson BN; Mojaverian P; Boppana VK
    J Toxicol Environ Health; 1983; 12(2-3):213-22. PubMed ID: 6655731
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of sulindac and indomethacin on renal prostaglandin synthesis.
    Sedor JR; Williams SL; Chremos AN; Johnson CL; Dunn MJ
    Clin Pharmacol Ther; 1984 Jul; 36(1):85-91. PubMed ID: 6428794
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of budesonide/formoterol pressurized metered-dose inhaler: randomized controlled trial comparing once- and twice-daily dosing in patients with asthma.
    Berger WE; Bleecker ER; O'Dowd L; Miller CJ; Mezzanotte W
    Allergy Asthma Proc; 2010; 31(1):49-59. PubMed ID: 20167145
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renal metabolism of sulindac: functional implications.
    Miller MJ; Bednar MM; McGiff JC
    J Pharmacol Exp Ther; 1984 Nov; 231(2):449-56. PubMed ID: 6436473
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ibuprofen and sulindac kinetics in alcoholic liver disease.
    Juhl RP; Van Thiel DH; Dittert LW; Albert KS; Smith RB
    Clin Pharmacol Ther; 1983 Jul; 34(1):104-9. PubMed ID: 6861431
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enterohepatic circulation of sulindac and metabolites.
    Dujovne CA; Pitterman A; Vincek WC; Dobrinska MR; Davies RO; Duggan DE
    Clin Pharmacol Ther; 1983 Feb; 33(2):172-7. PubMed ID: 6822030
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of sulindac and metabolites in plasma and urine by high-performance liquid chromatography.
    Stubbs RJ; Ng LL; Entwistle LA; Bayne WF
    J Chromatogr; 1987 Jan; 413():171-80. PubMed ID: 3558666
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The efficacy and safety of sulindac (400 mg vs 600 mg daily) in rheumatoid arthritis. A Canadian Multicentre Study.
    Atkinson M; Germain G; Lee P
    J Rheumatol; 1988 Jun; 15(6):1001-4. PubMed ID: 3047380
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of uremia and anephric state on the pharmacokinetics of sulindac and its metabolites in rats. II. Differential effects on the biliary excretion.
    Lin JH; Yeh KC; Duggan DE
    Drug Metab Dispos; 1985; 13(5):608-13. PubMed ID: 2865112
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sulindac reduces the urinary excretion of prostaglandins and impairs renal function in cirrhosis with ascites.
    Quintero E; Ginés P; Arroyo V; Rimola A; Camps J; Gaya J; Guevara A; Rodamilans M; Rodés J
    Nephron; 1986; 42(4):298-303. PubMed ID: 3515219
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Once-daily dosing of a new ultrasustained-release theophylline preparation.
    Van den Brande P; Nys J; Tjandramaga TB; Verhelst F; Demedts M
    Respiration; 1987; 52(2):144-53. PubMed ID: 3671893
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the effects of sulindac with other cyclooxygenase inhibitors on prostaglandin excretion and renal function in normal and chronic bile duct-ligated dogs and swine.
    Zambraski EJ; Chremos AN; Dunn MJ
    J Pharmacol Exp Ther; 1984 Mar; 228(3):560-6. PubMed ID: 6423807
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Placental transfer of sulindac and its active sulfide metabolite in humans.
    Kramer WB; Saade G; Ou CN; Rognerud C; Dorman K; Mayes M; Moise KJ
    Am J Obstet Gynecol; 1995 Mar; 172(3):886-90. PubMed ID: 7892880
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety profile of fluticasone furoate administered once daily in the morning or evening: a randomized, double-blind, double-dummy, placebo-controlled trial in adult and adolescent patients with persistent bronchial asthma.
    Medley H; Orozco S; Allen A
    Clin Ther; 2012 Aug; 34(8):1683-95. PubMed ID: 22796247
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acute renal effects of sulindac and indomethacin in chronic renal failure.
    Berg KJ; Talseth T
    Clin Pharmacol Ther; 1985 Apr; 37(4):447-52. PubMed ID: 3884224
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Measurement of sulindac and its metabolites in human plasma and urine by high-performance liquid chromatography.
    Swanson BN; Boppana VK
    J Chromatogr; 1981 Sep; 225(1):123-30. PubMed ID: 7298740
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sulindac: therapeutic implications of the prodrug/pharmacophore equilibrium.
    Duggan DE
    Drug Metab Rev; 1981; 12(2):325-37. PubMed ID: 7040018
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.